EGFRseek - SeekIn

 
seek and you will find

EGFRseek^TM

Treatment guidelines for non-small cell lung cancer

The EGFR mutation is the most common driver mutation in non-small cell lung cancer (NSCLC) and serves as a critical therapeutic target guiding treatment decisions.
EGFRseek™, utilizing the Bio-Rad QX200™ Droplet Digital PCR platform, performs highly sensitive, absolute quantitative detection of EGFR mutations in peripheral blood. This advanced methodology covers key mutations including exon19 deletion, exon20 T790M, and exon21 L858R, and enables earlier prediction of drug resistance and disease progression, more precise minimal residual disease (MRD) monitoring.
Specifications

◉ Indicated subjects: non-small cell lung cancer patients with EGFR mutations
◉ Sample requirements: 4 mL peripheral blood
◉ Turnaround time (TAT): 3 working days
How it works
Order
Consult your doctor to order through a local healthcare partner
Blood draw
4 mL of peripheral blood is collected and delivered to the central lab
Testing
Detection is performed using droplet digital PCR platform
Reporting
Results are ready within 3 working days after the sample arrives at the central lab
References
1.Xu Q, Zhu Y, Bai Y, et al. Detection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction. Onco Targets Ther. 2015;8:1533-1541. Published 2015 Jun 22. doi:10.2147/OTT.S84938.
2.Lee JY, Qing X, Xiumin W, et al. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget. 2016;7(6):6984-6993. doi:10.18632/oncotarget.6874.

EGFRseekTM

Treatment guidelines for non-small cell lung cancer

The EGFR mutation is the most common driver mutation in non-small cell lung cancer (NSCLC) and serves as a critical therapeutic target guiding treatment decisions.

Specifications

How it works

Order

Blood draw

Testing

Reporting

References

EGFRseek^TM